1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : BIOTECH
  4. RAIN ONCOLOGY INC
Rain Oncology Inc
XNAS: RAIN
Download real time
2.03 -0.07 (-3.33%)
New 52W Low today
33,170
XNAS Volume
High volume today

XNAS 05 May, 2026 2:48 PM (EDT)

Watchlist

Portfolio

Alert


Insider Trading disclosures for Rain Oncology Inc

The latest disclosure was made by Erik Atkisson in Rain Oncology Inc where a trade of 120,000 Stock Option (Right to Buy) done was reported to US exchanges on March 2, 2023.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Erik Atkisson General Counsel and CCO Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Mar 2023 120,000 120,000 - - Stock Option (Right to Buy)
Robert Doebele See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Feb 2023 123,325 123,325 - - Stock Option (Right to Buy)
Nelson Cabatuan VP of Finance & Admin Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Feb 2023 65,325 65,325 - - Stock Option (Right to Buy)
Avanish Vellanki Director, Chairman and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Feb 2023 318,600 318,600 - - Stock Option (Right to Buy)
Richard P. Bryce Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Feb 2023 110,000 110,000 - - Stock Option (Right to Buy)
Franklin M. Berger Director Purchase of securities on an exchange or from another person at price $ 7.80 per share. 21 Nov 2022 45,000 928,207 - 7.8 351,000 Common Stock
Franklin M. Berger Director Purchase of securities on an exchange or from another person at price $ 8.27 per share. 21 Nov 2022 77,000 1,005,207 - 8.3 636,790 Common Stock
Franklin M. Berger Director Purchase of securities on an exchange or from another person at price $ 5.83 per share. 08 Nov 2022 42,881 883,207 - 5.8 249,996 Common Stock
Robert Doebele See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 06 Jul 2022 3,890 5,000 - - Stock Option (Right to Buy)
Robert Doebele See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. 06 Jul 2022 3,890 476,827 - 4.0 15,366 Common Stock
Tran B. Nguyen Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2022 20,000 20,000 - - Stock Option (Right to Buy)
Gorjan Hrustanovic Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2022 20,000 20,000 - - Stock Option (Right to Buy)
Stefani A. Wolff Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2022 20,000 20,000 - - Stock Option (Right to Buy)
Peter Radovich Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2022 20,000 20,000 - - Stock Option (Right to Buy)
Avanish Vellanki Director, Chairman and CEO, Ten Percent Owner Purchase of securities on an exchange or from another person at price $ 2.29 per share. 01 Jun 2022 25,000 2,471,627 - 2.3 57,250 Common Stock
Franklin M. Berger Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jun 2022 20,000 20,000 - - Stock Option (Right to Buy)
Avanish Vellanki Director, Chairman and CEO, Ten Percent Owner Gift of securities by or to the insider at price $ 0.00 per share. 14 Apr 2022 59,618 2,446,627 - 0 Common Stock
Avanish Vellanki Director, Chairman and CEO, Ten Percent Owner Gift of securities by or to the insider at price $ 0.00 per share. 14 Apr 2022 59,618 79,283 - 0 Common Stock
Robert Doebele See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. 13 Apr 2022 3,000 472,937 - 4.0 11,850 Common Stock
Robert Doebele See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 13 Apr 2022 3,000 8,890 - - Stock Option (Right to Buy)
Robert Doebele See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. 31 Mar 2022 2,000 469,937 - 4.0 7,900 Common Stock
Robert Doebele See Remarks Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 31 Mar 2022 2,000 11,890 - - Stock Option (Right to Buy)
Avanish Vellanki Director, President and CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. 11 Mar 2022 14,468 2,837,009 - 4 57,872 Common Stock
Avanish Vellanki Director, President and CEO Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 11 Mar 2022 14,468 31,832 - - Stock Option (Right to Buy)
Avanish Vellanki Director, President and CEO Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Feb 2022 182,300 182,300 - - Stock Option (Right to Buy)
Robert Doebele EVP, Chief Scientific Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jan 2022 72,000 72,000 - - Stock Option (Right to Buy)
Nelson Cabatuan See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jan 2022 32,000 32,000 - - Stock Option (Right to Buy)
Richard P. Bryce Chief Medical Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jan 2022 53,064 53,064 - - Stock Option (Right to Buy)
Franklin M. Berger Director Purchase of securities on an exchange or from another person at price $ 14.30 per share. 21 Sep 2021 3,786 840,326 - 14.3 54,140 Common Stock
Franklin M. Berger Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 May 2021 24,000 24,000 - - Stock Option (Right to Buy)
Stefani A. Wolff Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 May 2021 24,000 24,000 - - Stock Option (Right to Buy)
Nelson Cabatuan See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 12 May 2021 6,000 6,000 - - Stock Option (Right to Buy)
Peter Radovich Director 27 Apr 2021 9,500 0 - - Series A Preferred Stock
Peter Radovich Director 27 Apr 2021 8,796 8,796 - - Common Stock
Robert Doebele EVP, Chief Scientific Officer 27 Apr 2021 4,932 467,937 - - Common Stock
Robert Doebele EVP, Chief Scientific Officer 27 Apr 2021 5,327 0 - - Series A Preferred Stock
Avanish Vellanki Director, President and CEO 27 Apr 2021 11,212 2,372,541 - - Common Stock
Avanish Vellanki Director, President and CEO 27 Apr 2021 12,108 0 - - Series A Preferred Stock
Franklin M. Berger Director Purchase of securities on an exchange or from another person at price $ 17.00 per share. 23 Apr 2021 120,000 120,000 - 17 2,040,000 Common Stock
Franklin M. Berger Director 23 Apr 2021 578,397 0 - - Series B Preferred Stock
Franklin M. Berger Director 23 Apr 2021 189,998 0 - - Series A Preferred Stock
Franklin M. Berger Director 23 Apr 2021 535,601 836,540 - - Common Stock
Franklin M. Berger Director 23 Apr 2021 175,939 300,939 - - Common Stock
Franklin M. Berger Director Purchase of securities on an exchange or from another person at price $ 15.78 per share. 23 Apr 2021 5,000 125,000 - 15.8 78,900 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters